GLG Pharma

A Report on the Patient Testing Market

follower @ GLG Pharma

Published on Dec 21, 2018

Hello all, just thought I would share this with the investors and anyone else that is wondering how big the application for Gx-C3 might be. While we are now focused on Ovarian Cancer, we have interests in other cancers as well, including breast cancer and thyroid as well as 30 other types that are upregulated with STAT3 (which causes metastasis among other problems for the patient). Please pass around and we need more investors! Our offering officially closes on January 21, 2019 so please pitch in and help us!!! We would greatly appreciate the help in raising funds! IVDRoverview.pdf